37.45
-2.42 (-6.07%)
| Penutupan Terdahulu | 39.87 |
| Buka | 39.17 |
| Jumlah Dagangan | 1,231 |
| Purata Dagangan (3B) | 1,779 |
| Modal Pasaran | 3,674,942,208 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 25 Nov 2025 |
| Margin Keuntungan | -26.41% |
| Margin Operasi (TTM) | 70.24% |
| EPS Cair (TTM) | -1.08 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -29.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 108.23% |
| Nisbah Semasa (MRQ) | 5.15 |
| Aliran Tunai Operasi (OCF TTM) | 61.15 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -6.46 M |
| Pulangan Atas Aset (ROA TTM) | -5.86% |
| Pulangan Atas Ekuiti (ROE TTM) | -26.22% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (GB) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | ARROWHEAD PHARMACEUTICALS INC A | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 5.0 |
| Osilator Teknikal | 4.0 |
| Purata | 1.13 |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS INC A | 4 B | - | - | - |
| PHARMA MAR SA PHARMA MAR ORD SH | 16 B | 1.08% | 14.69 | - |
| GENUS PLC ORD 10P | 2 B | 0.01% | 81.55 | 3.61 |
| BASILEA PHARMACEUTICA AG BASILE | 511 M | - | - | 6.18 |
| AVACTA GROUP PLC ORD 10P | 353 M | - | - | 2.35 |
| PROTHENA CORPORATION PLC PROTHE | 330 M | - | 7.53 | - |
|
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 13.02% |
| % Dimiliki oleh Institusi | 77.19% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |